GlassScriptPhysician profile
Harold J Pean
NPI 1013950484
$11,262.16
in general payments reported to CMS, 2019-2025
55 companies · $1,332 in 2025
The $1,332 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,230 · 2020: $2,447 · 2021: $2,454 · 2022: $1,635 · 2023: $1,039 · 2024: $1,126 · 2025: $1,332.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,480 · Education: $16.03.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,480.18 |
| Education | $16.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,305.88 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,246.21 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $806.06 | 2019-2023 | Xarelto |
| Lilly USA, LLC | $664.36 | 2020-2025 | Mounjaro, Trulicity, Jardiance |
| Glaxosmithkline, LLC. | $620.48 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Pfizer INC. | $604.78 | 2019-2025 | |
| Amgen INC. | $529.99 | 2019-2025 | Repatha, Otezla, Evenity |
| Astrazeneca Pharmaceuticals LP | $457.76 | 2019-2025 | Farxiga, Airsupra |
| Astellas Pharma US INC | $448.70 | 2019-2025 | Veozah |
| Mylan Specialty L.P. | $424.62 | 2021-2024 | Yupelri, Yupelri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $412.03 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $350.54 | 2019-2022 | |
| Dexcom, INC. | $309.09 | 2021-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Amarin Pharma, INC. | $275.83 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $270.82 | 2019-2025 | Verquvo |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harold Pean listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.